NTT Com Wins Two MEF 3.0 Proof of Concept Awards
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO: 9432), announced today it received MEF 3.0 Proof of Concept Awards in two categories, “MEF3.0 SD-WAN Implementation 2019” and “Network Slicing Implementation 2019,” during the MEF 3.0 Proof of Concept Showcase event held in the U.S. city of Los Angeles from November 18 to 22.
The showcase was organized by the Metro Ethernet Forum (MEF), a global telecom industry alliance with more than 220 members. NTT Com attended the showcase to introduce an SD-WAN1 service and a 5G-related proof of concept (PoC)2, joining other telecom carriers and manufacturers that presented their own initiatives for judging.
About MEF Awards
https://www.mef.net/2019_MEF_Awards
MEF3.0 SD-WAN Implementation 2019
NTT Com’s orchestrated virtualized multivendor SD-WAN services received the award presented for the best SD-WAN service in compliance with MEF specifications. The NTT Com service was recognized for enabling lifecycle3 management and operation of multiple SD-WAN products with a unified portal and white box CPEs4.
SD-WAN is not a standardized technology, so many unique network devices exist, requiring operation methods to be designed to each manufacturer’s technologies. To solve this problem, NTT Com conducted a PoC to implement unified control of multiple SD-WAN products based on MEF-standardized SD-WAN specifications, data models, interfaces and test methods.
NTT Com collaborated with partner companies to co-develop the orchestrated virtualized multivendor SD-WAN services in conformance with the MEF70 and MEF SD-WAN Presto API standard5. The service uses a universal CPE platform, enabling multiple SD-WAN products to be installed on the white box CPE, and a unified configuration portal, enabling unified control of multiple SD-WAN products.
The partner companies involved in co-development are ADVA, Netcracker Technology, Silver Peak, Spirent Communications, Versa Networks and NEC Corporation.
Network Slicing Implementation 2019
The award for the best network slicing6 technology was presented to NTT Com collaborating with partner companies for its 5G xHaul Sharing Slices with LSO Orchestration, which enables automatic control by using network slices for multiple-operator interconnection.
5G technology is anticipated to be used in companies and local governments in addition to telecom carriers by utilizing to such as private 5G service. The new network system that the various companies can use in common like this is necessary to build the network effectively.
NTT Com collaborated with partner companies to co-develop the shared xHaul architecture in conformance with the MEF standard by utilizing network slicing technology.
The architecture creates end-to-end network slices by multi-operator collaboration to share the access network (xHaul) required for 5G service.
The partner companies that contributed to the solution are NTT Corporation and Okinawa Open Laboratory.
SDN7 and network functions virtualization (NFV)8 technologies continue to be advanced through open-source development projects and by standardization organizations. Going forward, NTT Com aims to help drive the development of SDN and NFV technologies through its participation in MEF and ONF9.
|
1: |
SD-WAN simplifies the management and operation of a WAN by separating the networking hardware from its control mechanism. |
|
2: |
Verification and demonstration of prototype development to demonstrate new concepts, theories, principles and ideas for commercialization and service development |
|
3: |
Service provision process covering application, start of use, settings and quality control |
|
4: |
Separates CPE hardware and software functions and allows software selection and installation for each application |
|
5: |
MEF specification for SD-WAN: https://www.mef.net/resources/technical-specifications/download?id=122&fileid=file1 |
|
6: |
Virtual division of network according to characteristics, such as low latency, wide bandwidth or high reliability, by application purpose |
|
7: |
Technologies that dynamically control network configuration and settings using software |
|
8: |
Method for operating network devices as software on virtualized infrastructure of general-purpose servers |
|
9: |
Open Networking Foundation, which standardizes SDN technologies and develops open source software |
Related links
- Orchestrated Virtualized Multi-Vendor SD-WAN Services
- 5G xHaul Sharing as Slices with LSO Orchestration
About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 450,000m2 of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120006059/en/
Contact information
For more information
Ryu Kanishima
Service Strategy Department
NTT Communications
Mail: mgr-nwcore-td@ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom